Arca
Skip to content
Tools
Tools

RRM1, RRM2B: Ribonucleotide reductase

Complex in Homo sapiens that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on RRM1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved0

    Phase 31

    • Triapine

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        TriapinePhase 3Rousselot BVBASmall moleculeInhibitorRibonucleotide reductase inhibitor8

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Performance at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory ProblemsTriapineNot applicableRecruitingRousselot BVBAFeb 4, 2026
        Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or AstrocytomaTriapinePhase 1RecruitingNational Cancer Institute (NCI)Mar 6, 2025
        Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent GlioblastomaTriapinePhase 1RecruitingNorthwestern UniversityMay 13, 2024
        Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine TumorsTriapinePhase 2Active, not recruitingNational Cancer Institute (NCI)Feb 13, 2023
        Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of HysterectomyTriapineEarly phase 1Active, not recruitingNational Cancer Institute (NCI)Jul 31, 2020
        Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine TumorsTriapinePhase 1Active, not recruitingNational Cancer Institute (NCI)Jan 21, 2020
        Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal CancerTriapinePhase 1Active, not recruitingNational Cancer Institute (NCI)Nov 4, 2015
        Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal CancersTriapinePhase 3Active, not recruitingNational Cancer Institute (NCI)Jun 9, 2015

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3301398, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.